Bafna Pharmaceuticals gained 4.81% to Rs 32.70 at 15:05 IST on BSE, after ratings agency CRISIL upgraded short term and long term rating of the company in respect of total bank facilities.
The announcement was made during market hours today, 19 November 2014.
Meanwhile, the BSE Sensex was down 182.54 points, or 0.65%, to 27,980.75
On BSE, so far 25,625 shares were traded in the counter as against average daily volume of 44,298 shares over the past one quarter.
The stock hit a high of Rs 33.65 and a low of Rs 31.20 so far during the day. The stock had hit a 52-week high of Rs 38.50 on 2 July 2014 and a 52-week low of Rs 16.90 on 31 March 2014.
The stock had underperformed the market over the past one month till 18 November 2014, rising 5.05% compared with the Sensex's 7.87% rise. The scrip, however, outperformed the market in past one quarter, gaining 24.55% as against Sensex's 6.72% rise.
The small-cap company has an equity capital of Rs 18.66 crore. Face value per share is Rs 10.
Bafna Pharmaceuticals said that CRISIL has upgraded the rating as CRISIL BB-/stable (Upgraded from CRISIL D) for long term rating & CRISIL A4+ (Upgraded from CRISIL D) for short term rating in respect of total bank facilities.
Bafna Pharmaceuticals reported 2691.6% surge in net profit to Rs 33.22 crore on 50.6% slide in net sales to Rs 23.19 crore in Q2 September 2014 over Q2 September 2013.
Bafna Pharmaceuticals is a pharmaceutical company engaged in the manufacture of drugs and medicines. The company's products consist of various formulations in solid orals and liquid orals.
Powered by Capital Market - Live News
